Skip to content
lifestyle.childcarepartnerships.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Mineralys Therapeutics, Inc.
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
March 12, 2026
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
March 9, 2026
←
Previous Page
1
2
3